Skip to content
    SPRO
    Earnings call· Jun 2026(Q2 FY26)

    Spero Therapeutics Q2 FY26 earnings call SPRO

    Aug 12, 2026 Source

    Executive summary

    Spero Therapeutics Q2 FY26 — FDA Approval, Pipeline Repositioning, and Strategic Financing

    Spero Therapeutics completed a transformative quarter, securing FDA approval for Utebzi, which enabled a strategic pivot to immunology. The company in-licensed SP001, a promising CD40 ligand antibody, and bolstered its financial position with a significant non-dilutive financing, extending its cash runway. This strategic realignment, supported by new leadership, positions Spero to advance its lead immunology asset into clinical development, focusing on high unmet medical needs.

    Highlights

    4

    • FDA approved Utebzi, the first oral carbapenem for cUTI, on June 17, 2026.

    • In-licensed SP001, a CD40 ligand antibody, for immune-mediated diseases with an estimated $1.1 billion total contingent deal value.

    • Closed $105 million nondilutive, nonrecourse royalty financing, extending cash runway into H2 2029.

    • Hired Dr. Debra Zack as Chief Medical Officer to lead immunology pipeline development.

    Concerns

    3

    • Net loss increased to $9.6 million in Q2 FY26 from $1.7 million in Q2 FY25.

    • Diluted net loss per share increased to $0.16 in Q2 FY26 from $0.03 in Q2 FY25.

    • Revenue for Q2 FY26 was $0, down from $14.2 million in Q2 FY25 due to prior collaboration revenue being fully realized.

    Guidance & targets

    3
    CategoryTargetConfidence
    Cash runway
    Into the second half of 2029
    high materiality
    High
    SP001 Phase II trial start
    Expected to begin in the second quarter of 2027
    high materiality
    High
    Utebzi commercial availability in U.S.
    Second half of this year
    medium materiality
    High

    Operational metrics

    6
    Cash and cash equivalents
    $50.8 million
    Q2 FY26

    As of June 30, 2026, prior to the net proceeds from the royalty financing completed in July 2026.

    R&D expenses
    $3.4 milliondown from $10.7 million in Q2 FY25
    Q2 FY26

    Decrease primarily due to reduced clinical activity following the early completion of the Phase III trial for Utebzi in H1 2025, and lower personnel-related costs.

    G&A expenses
    $6.5 millionup from $5.9 million in Q2 FY25
    Q2 FY26

    Increase primarily due to increases in business development, legal, and consulting expenses.

    Royalty financing principal and interest rate
    10%
    Annual

    The $105 million senior secured notes carry a 10% annual interest rate and a 9-year maturity.

    Spero retention of Utebzi proceeds
    35%
    Post-repayment

    After the $105 million notes are repaid, Spero retains 35% of additional GSK milestone and royalty proceeds.

    Upfront payment for SP001
    $35 million
    One-time

    This payment to Innovent is funded by the royalty financing proceeds.

    Industry KPIs

    2
    MetricValueDetails
    Pipeline read out calendarPhase II trial for SP001 in IgG4-RD
    Regulatory approvals filingsUtebzi (tebipenem pivoxil)

    Deals & partnerships

    3
    GSKExclusive commercialization rights for Utebzi

    GSK holds exclusive commercialization rights worldwide for Utebzi, excluding certain Asian territories where Meiji retains rights. Utebzi was FDA approved on June 17, 2026.

    Innovent BiologicsExclusive worldwide rights (excluding Greater China) to develop and commercialize SP001$1.1 billion

    Agreement announced on July 8, 2026, for SP001 (IBI355), a third-generation fully humanized Fc silent IgG1 monoclonal antibody targeting CD40 ligand.

    Healthcare Royalty (affiliates of KKR)Nondilutive, nonrecourse royalty financing$105 million9-year maturity

    Financing announced and closed on July 8, 2026. The notes are nonrecourse to Spero and its other assets.

    Risks & headwinds

    2
    Utebzi launch and sales risk

    Nonrecourse financing structure protects Spero's other assets.

    Mitigation: The $105 million royalty financing is nonrecourse to Spero, meaning Spero's other assets are not exposed to Utebzi launch or sales risk.

    Relentless nature of IgG4-RD disease

    Patients continue on a cycle of remission and relapse with current treatments.

    Mitigation: SP001 aims to provide durable long-term disease control by modulating the conversation between immune cells upstream, potentially smoothing out the treatment regimen and preventing further damage.

    What to watch in Q3 FY26

    3

    Utebzi commercial availability in U.S.

    Next quarter
    CurrentExpected in H2 2026
    TargetConfirmation of availability and initial commercialization updates from GSK

    Why it matters

    Utebzi's launch by GSK is the source of future milestone and royalty payments, which underpin Spero's royalty financing and long-term financial health.

    GSK expects Utebzi to be available to U.S. patients in the second half of this year.

    Q&A highlights

    2

    How will clinical benefit be assessed for SP001 in IgG4-RD, considering flare suppression, symptom control, remission, and steroid/DMARD reduction? How will it be positioned in the market given existing therapies like B-cell depleters and Uplizna?

    The Phase II trial will focus on symptom control, safety, and reduction in steroid/DMARD use. Phase III would address flare suppression. SP001's upstream CD40 ligand mechanism differentiates it from B-cell depleters by inhibiting crosstalk between T cells, innate immunity, and B cells, aiming for continuous disease control rather than just flare management, potentially smoothing out treatment regimens.

    “I can see where a molecule such as this by continuing control of the disease, you smooth out that treatment regimen so that the patient continues to be under control, thereby not adding to the damage that may already be there and progressing to further damage.”

    asked by Raghuram Selvaraju · answered by Debra Zack

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Repositioning to Immunology

    Spero Therapeutics has strategically repositioned itself as an immunology-focused company following the FDA approval of Utebzi. This pivot is anchored by the in-licensing of SP001, a third-generation fully humanized Fc silent IgG1 monoclonal antibody targeting CD40 ligand. The company aims to address high unmet medical needs in immune-mediated diseases, leveraging its experienced team for clinical development and commercialization.

    02

    Utebzi FDA Approval and Commercialization

    On June 17, 2026, the FDA approved Utebzi (tebipenem pivoxil) for complicated urinary tract infections, including pyelonephritis, caused by certain susceptible pathogens. This marks Utebzi as the first and only oral carbapenem antibiotic approved in the U.S. The approval was based on the PIVOT-PO Phase III study, which was stopped early for efficacy in May 2025. GSK holds exclusive commercialization rights worldwide (excluding certain Asian territories), and expects Utebzi to be available to U.S. patients in the second half of 2026.

    03

    SP001 In-Licensing and Development Plan

    Spero announced an exclusive license agreement with Innovent Biologics for SP001 (IBI355) on July 8, 2026, granting Spero worldwide rights excluding Greater China. SP001 has completed two Phase I studies in healthy volunteers and a Phase Ib study in primary Sjogren's disease. The company intends to advance SP001 into a Phase II trial for immunoglobulin G4-related disease (IgG4-RD), with initiation expected in Q2 2027. The planned Phase II trial will be open-label, with 6 monthly dosing, enrolling up to 15 patients in each of two dosing arms.

    04

    Strategic Financing and Balance Sheet Strength

    On July 8, 2026, Spero closed a $105 million nondilutive, nonrecourse royalty financing with affiliates of Healthcare Royalty, a KKR business. This financing involved a special purpose subsidiary issuing senior secured notes with a 10% annual interest rate and a 9-year maturity, payable from GSK's Utebzi milestone and royalty payments. Spero retains 35% of additional GSK proceeds after note repayment. This transaction significantly strengthened the balance sheet, providing capital for the new immunology strategy and extending the cash runway into the second half of 2029.

    05

    Leadership Appointment

    Dr. Debra Zack joined Spero as Chief Medical Officer on August 3, 2026. Dr. Zack is a Board-certified rheumatologist with a PhD in immunology and extensive drug development experience from companies like Amgen, Xencor, and Novartis. She will lead the clinical development strategy for SP001 and the broader immunology pipeline.

    06

    IgG4-RD Market Opportunity and SP001 Differentiation

    IgG4-RD is a serious chronic fibroinflammatory disease affecting 20,000 to 40,000 diagnosed patients in the U.S., with diagnosis rates expected to increase due to a recently implemented disease-specific diagnostic code (October 2023). Current treatments are off-label steroids or B-cell depleters, which lead to cycles of remission and relapse. SP001, by targeting CD40 ligand, aims to offer a differentiated approach by disrupting the pathologic interaction between T cells and B cells, potentially modulating multiple components of the disease process simultaneously and providing more durable long-term control.

    AI-generated summary of the company’s earnings call. Not investment advice.